Royalty Pharma plc (RPRX): Total Liabilities
$9.91B
As of 2025-12-31
$10.03B
As of 2026-06-30
+10.8%
3-year compound annual growth
+10.1%
5-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $9.91B | +25.7% | 2026-02-11, Balance as of period end |
| 2024-12-31 | $7.88B | +25.1% | 2026-02-11, Balance as of period end |
| 2023-12-31 | $6.30B | -13.6% | 2025-02-12, Balance as of period end |
| 2022-12-31 | $7.29B | +0.3% | 2024-02-15, Balance as of period end |
| 2021-12-31 | $7.27B | +18.7% | 2023-02-15, Balance as of period end |
| 2020-12-31 | $6.12B | -2.9% | 2022-02-15, Balance as of period end |
| 2019-12-31 | $6.31B | n/a | 2021-02-24, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| Royalty Pharma plc (RPRX) | 2025-12-31 | $9.91B | +25.7% |
| Sarepta Therapeutics, Inc. (SRPT) | 2025-12-31 | $2.21B | -9.3% |
| United Therapeutics Corp (UTHR) | 2025-12-31 | $783.80M | -14.8% |
| BioMarin Pharmaceutical Inc (BMRN) | 2025-12-31 | $1.51B | +13.2% |
| PTC Therapeutics, Inc. (PTCT) | 2025-12-31 | $3.10B | +10.7% |
| Alnylam Pharmaceuticals, Inc. (ALNY) | 2025-12-31 | $4.18B | +0.1% |
| Phibro Animal Health Corp (PAHC) | 2026-06-30 | $1.12B | +3.8% |
| Alkermes plc. (ALKS) | 2025-12-31 | $667.70M | +13.1% |
| Perrigo Co PLC (PRGO) | 2025-12-31 | $5.60B | +5.1% |
Compare RPRX, SRPT, UTHR, BMRN side by side · Screen every company in Pharmaceutical Preparations ↗